Mal-PEG2-VCP-Eribulin

Cat. No.: HY-128870

CAS No.: 2130869-18-8

Molecular Formula: $C_{70}H_{99}N_7O_{21}$

Molecular Weight: 1374.57

Target: Drug-Linker Conjugates for ADC

Pathway: Antibody-drug Conjugate/ADC Related

Storage: 4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 10 mg/mL (7.28 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	0.7275 mL	3.6375 mL	7.2750 mL
5 mM	0.1455 mL	0.7275 mL	1.4550 mL
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates[1][2][3].

IC_{50} & Target

Traditional Cytotoxic Agents

REFERENCES

[1]. Watanabe K, et al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4;10(2):161-174.

[2]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.

[3]. Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA